Massive layoff round will happen in 2H 2018

[anonymous]

Actually, it's neither. His name is Lars Fruergaard Jorgensen. If you're going to attack a guy for doing a bad job, you might as well get his name right, don't you think? And, I couldn't say whether or not the BoD is 'loosing' (hint: the word is 'losing') trust in him or not, but his predecessors put all their eggs in the US basket, and pricing pressure is going up and margins are going down. I'm not sure anyone could do a great job in that environment.

Pricing pressure up and margins down mean downsizing sooner rather than later -who cares how all the eggs ended up in the US basket ? Lars whatever-the-last-name definitely is a loser if he fails to take serious action now.

 

[anonymous]

Pricing pressure up and margins down mean downsizing sooner rather than later -who cares how all the eggs ended up in the US basket ? Lars whatever-the-last-name definitely is a loser if he fails to take serious action now.

Good point, but Lars Fruerfuck Spears clueless.

 

[anonymous]

Good point, but Lars Fruerfuck Spears clueless.

Please maintain your integrity at all times. Lars WTF is our CEO. He has no clue about anything but to run a minor pigfarm. Treat him with outmost respect. Any pig deserves at least that. Just think about what the Danes will put in front of us once Lars WTF fails. Guess what; We will get another Lars WTF immediately...

 

[anonymous]

Lars F(ing) Jargon-say will throw his hand grenade next Wednesday. He will announce uncoordinated layoffs by each EVP, and I'll bet you we will get the lion share of the firings. Home office people in Denmark will hardly be touched, maybe with the exception of researchers. Then he will try and down play the whole thing by using his usual jargon. Agility, bold, simplicity. Watch the News on Wednesday.

 

[anonymous]

Its about to get uglier than anyone imagined.

 

[Anonymous]

You have to be a very bored, very miserable, douchebag to get on here simply to stir up rumors and create panic. While there are some exceptions, most people work for Novo because they are honest, hardworking individuals, who enjoy providing a nice life for their families. The instability of that is certainly nothing to joke about. If you don't have facts, find your drama elsewhere. Netflix has a variety of shows that you can binge watch. Just shut up and stay off this thread unless you have something of real value to contribute (good or bad).

 

[anonymous]

You have to be a very bored, very miserable, douchebag to get on here simply to stir up rumors and create panic. While there are some exceptions, most people work for Novo because they are honest, hardworking individuals, who enjoy providing a nice life for their families. The instability of that is certainly nothing to joke about. If you don't have facts, find your drama elsewhere. Netflix has a variety of shows that you can binge watch. Just shut up and stay off this thread unless you have something of real value to contribute (good or bad).

It’s you doing it.

 

[anonymous]

it’s so stupid to have the same rep’s working in the same territory calling on the same doctors. That’s called a 1992 business plan. In 2018 everyone has their own territory. Total waste of money to do that. BI ... Pfizer gsk good god wake up “teams “ are headed to a bear market

 

[anonymous]

Lars F(ing) Jargon-say will throw his hand grenade next Wednesday. He will announce uncoordinated layoffs by each EVP, and I'll bet you we will get the lion share of the firings. Home office people in Denmark will hardly be touched, maybe with the exception of researchers. Then he will try and down play the whole thing by using his usual jargon. Agility, bold, simplicity. Watch the News on Wednesday.

If home office in Denmark isn't being touched, why the initial concern regarding trade unions?

 

[anonymous]

R&D in Denmark will be hit hard again, just like in 2016. Mgmt in their wisdom have "discovered" that way too much resources are spent on insulin and GLP-1 projects and too little on "new stuff", like CV, fatty liver and so.

Complete disaster: Executive Mgmt has been asleep at the wheel since 2016 layoffs and only realised at the recent portfolio review how things are faring in R&D. So much for executive oversight and strategic direction. Could well turn out that they have to fire a lot of seasoned old timers and, more or less at the same time, hire a lot of new guys who know about CV and all that!

#inovertheirheads #MKThastogo

 

[anonymous]

R&D in Denmark will be hit hard again, just like in 2016. Mgmt in their wisdom have "discovered" that way too much resources are spent on insulin and GLP-1 projects and too little on "new stuff", like CV, fatty liver and so.

Complete disaster: Executive Mgmt has been asleep at the wheel since 2016 layoffs and only realised at the recent portfolio review how things are faring in R&D. So much for executive oversight and strategic direction. Could well turn out that they have to fire a lot of seasoned old timers and, more or less at the same time, hire a lot of new guys who know about CV and all that!

#inovertheirheads #MKThastogo

R&D Denmark should be hit harder than in 2016. The marginal improvement R&D strategy has been dead for years. Big mistake if directions have not been substantially refocused long ago. Current R&D management obviously does not have sufficient competence to lead such change.

 

[anonymous]

Realize that when another "generic" basal insulin hits the market (Merck), the basal market will become commoditized just like the rapid acting market. Novo is all in on semaglitide! Let's hope it delivers or we all will be looking for jobs!

 

[anonymous]

Realize that when another "generic" basal insulin hits the market (Merck), the basal market will become commoditized just like the rapid acting market. Novo is all in on semaglitide! Let's hope it delivers or we all will be looking for jobs!

Unfortunately for NNI, it already is.

 

[anonymous]

so when do we find out? This week or next? Anybody in the know?

 

[anonymous]

Realize that when another "generic" basal insulin hits the market (Merck), the basal market will become commoditized just like the rapid acting market. Novo is all in on semaglitide! Let's hope it delivers or we all will be looking for jobs!

I doubt Merck's generic glargine will get to the market within the next 2 years or more. The basal market is well under way to a commodity market anyway. Sanofi has a generic version of fast acting Aspart on its way. Semaglutide will provide some transient stability to the business, but generic Victoza (including weekly versions) will also be approaching. Unless Novo can buy some radically new drugs to their portfolio in the next few years, we will see the company gradually shrink starting with about 3,000 layoff's this fall. Novo's internal R&D has proved incapable of producing anything but marginal improvement.

 

[anonymous]

O-O-O-----Obesity!

 

[anonymous]

Why o-o-o Obesity?? We gone??

 

[anonymous]

why o-o-o Obesity?? We done??

 

[anonymous]

why obesity? What’s up??

 

[anonymous]

O-O-O-----Obesity!

Obesity is definitely a nice try, but there appears to be no clear reimbursement pattern to get treatment into larger "patient" populations. Eat responsibly still is a more sustainable bet for a company promoting the triple bottom line.